Agree with all the above comments. The potential is huge. I wonder what data FDA saw to grant the FTD.
Recently I glanced back to the Ann’s dating till 2017 when the company’s target was MS and that failed and the company had a different name. While not dwelling on it I decided to focus on the present. Let’s hope this incarnation and this drug + disease target will help us get across the line.
Ann: FDA Fast Track Designation for Narmafotinib, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $114.3M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.5¢ | 22.5¢ | $1.376M | 5.901M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 88273 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 1112670 | 11 |
View Market Depth
| Last trade - 12.28pm 30/07/2025 (20 minute delay) ? |
| ATX (ASX) Chart |